Mode
Text Size
Log in / Sign up

NewSTeP protocol using single-pill combinations for hypertension is currently being evaluated in a trialNew trial tests single-pill combinations for high blood pressure

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that this is a trial protocol; no clinical results or efficacy data are currently available.

The study is a randomized clinical trial designed to evaluate the New Standardised TrEatment Protocol (NewSTeP). The study population consists of 300 adults with hypertension who are either untreated or currently receiving one blood pressure-lowering drug and require treatment initiation or intensification. The trial is being conducted in tertiary healthcare centres in India.

The intervention group receives the NewSTeP protocol, which incorporates the initial or early use of single-pill combinations (SPCs). The comparator group receives usual care. The primary outcome is the change in home-measured mean systolic blood pressure from randomization to month 6. Secondary outcomes include the proportion of participants achieving blood pressure control, change in diastolic blood pressure, incidence of adverse events of special interest, treatment adherence, treatment modification, and time to blood pressure control.

No results are currently reported for any primary or secondary outcomes. Safety data, including adverse events and tolerability, are not yet available. A major limitation is that trial results are not anticipated until October 2026. Clinical application is currently limited as the study is in the protocol phase.

How this fits prior evidence

How this fits prior evidence: This trial addresses a gap in the management of hypertension by evaluating a specific standardized protocol using single-pill combinations. While prior coverage included non-pharmacological interventions like Tai Chi to reduce blood pressure and syndrome-informed Traditional Chinese Medicine to reduce blood pressure in patients with comorbid hypertension and insomnia, this study focuses on a pharmacological intervention strategy in the Indian context.

Managing high blood pressure can be difficult when patients have to take multiple pills every day. This makes it hard to stay consistent with treatment. To address this, a new trial is testing a standardized treatment protocol that uses single-pill combinations. These are medications that combine two or more blood pressure-lowering drugs into one single pill.

Researchers are testing this approach with 300 adults in India who currently have high blood pressure. The goal is to see if starting with these combined pills helps patients reach their target blood pressure faster and more reliably than the usual care they receive today.

Because this study is currently in the design and protocol phase, the final results are not available yet. The team will collect data on blood pressure changes, patient safety, and how well people stick to their daily routines over a six-month period. Results from the study are expected in late 2026.

What this means for you:
A new trial is testing if combining multiple medications into one pill helps manage high blood pressure.

Common questions

What is a single-pill combination?

A single-pill combination is a medication that combines two or more different blood pressure-lowering drugs into one single pill. This is designed to make it easier for patients to manage their condition because they only have to take one pill instead of multiple different ones.

Who is eligible for this study?

The study is looking for 300 adults with hypertension. This includes people who are not currently taking any medication for high blood pressure or those who are already taking one blood pressure-lowering drug but need to intensify their treatment.

Are the results of this trial available yet?

No, the results are not available yet. Because the study is currently in the design and protocol phase, the researchers do not expect to have the final data regarding effectiveness or safety until October 2026.

Study Details

Study typeRct
Sample sizen = 300
EvidenceLevel 2
PublishedSep 2026
View Original Abstract ↓
Background Hypertension is the leading modifiable risk factor for cardiovascular disease (CVD). Despite availability of blood pressure (BP)-lowering therapies, BP control rates remain suboptimal. Reluctance to initiate treatment with combination therapy and delayed treatment intensification contribute to poor control. Early use of single-pill combinations (SPCs) within standardised treatment protocols (STPs) may improve outcomes, but evidence from India is limited. Objective To evaluate the effectiveness and safety of a new STP incorporating initial or early use of SPCs compared with usual care among adults with hypertension. Methods The New Standardised TrEatment Protocol (NewSTeP) trial is a pragmatic, multicentre, randomized, parallel-group, open-label trial conducted in tertiary healthcare centres in India. Adults with hypertension who are untreated or receiving one BP-lowering drug and require treatment initiation or intensification (n = 300) will be randomized 1:1 to either a new STP incorporating early SPC therapy or usual care. Participants will be followed for 6 months. The primary effectiveness outcome is change in home-measured mean systolic BP from randomization to month 6. The primary safety outcome is discontinuation of trial drug due to adverse events. Secondary outcomes include proportion of participants achieving BP control, change in diastolic BP, incidence of adverse events of special interest, treatment adherence, treatment modification, and time to BP control. A process evaluation will assess reach, implementation, acceptability, and sustainability, while an economic evaluation will assess cost-effectiveness of the intervention. Results Between October 2025 and March 2026, 300 participants were randomized across nine sites (150 to New STP; 150 usual care) from 360 screened individuals. Final follow-up is expected in September 2026, with results anticipated in October 2026. Conclusions The NewSTeP trial will provide evidence on the effectiveness, safety, implementation, and cost-effectiveness of an SPC-based STP for hypertension management in India and inform future hypertension control strategies and policies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.